BioNTech Faces Major Q3 Losses While Pushing Oncology Advancements

Mainz, Monday, 3 November 2025.
BioNTech reported a Q3 2025 net loss of $924.8 million, a significant drop from last year’s profit. Despite losses, the company remains focused on innovative cancer treatment programs.